| Value | ₹0.10 Cr |
|---|
BSE filing, NSE: XTGLOBAL. Summary written from the filing by ALFA Finder's alert engine.
Xtglobal Infotech Ltd: key numbers
- Share price
- ₹29.25
- Market cap
- ₹392.4 Cr
- Revenue (annual)
- ₹368.7 Cr
- Net profit (annual)
- ₹11.53 Cr
- P/E (TTM)
- 30.9×Sector 23.2×
- Promoter holding
- 62.54%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Xtglobal Infotech Ltd
All →Xtglobal Infotech Employee Stock Options
XTGlobal Infotech allotted 46,500 equity shares to employees upon exercise of ESOPs/RSUs under its 2020 Stock Benefit Scheme. Paid-up capital increased to ₹13.417 Crore following the allotment.
Xtglobal Infotech Q2 FY27 Results: Net Profit ₹4.6 Cr, Up 35.3% YoY
Xtglobal Infotech Ltd reported revenue from operations of ₹89.7 Cr (-5.0% YoY) and net profit of ₹4.6 Cr (+35.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹4.6 Cr · +35.3% YoY
Xtglobal Infotech Board Meeting Date
XTGLOBAL INFOTECH Limited intimated a board meeting on 13 Nov 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026, plus ESOP and other business. Trading window closes 15 Nov 2026.
Xtglobal Infotech Other Announcement
Xtglobal Infotech Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b), detailing promoter and public equity holdings as of September 30, 2026.
Xtglobal Infotech Dividend
XTGlobal Infotech Limited has successfully completed the payment of an interim dividend of ₹0.05 per equity share for the financial year 2026-27.
Xtglobal Infotech Management Change
XTGlobal Infotech announced board composition changes approved at its 38th AGM, including the appointment of two directors, the re-appointment of one, and two cessations.
Other regulatory approval announcements
All →Senores Pharmaceuticals Regulatory Approval
Senores Pharmaceuticals disclosed that its subsidiary Ratnatris Pharmaceuticals' Mehsana facility received PIC/S GMP certification from Ukraine's SMDC. The certificate, issued 16 November 2026, opens a wider pathway to regulatory approvals.
Regal Entertainment & Consultants Regulatory Approval
Regal Entertainment received RBI approval for Satbir Singh's appointment as Executive Director. Shareholder approval is still pending, with the term running to April 4, 2028.
Biocon Regulatory Approval
Biocon received U.S. FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta, its fifth oncology biosimilar approved in the US. A global settlement with Genentech sets the earliest US launch in Q3 2028.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Binimetinib tablets, securing 180 days of generic drug exclusivity for the product.
United Breweries Regulatory Approval
United Breweries received BIADA's final order restoring its 42-acre Patna land allotment under the Amnesty Policy 2025, subject to conditions. Commercial production milestones must be met within 24 months.
Bhageria Industries Regulatory Approval
Bhageria Industries received EDQM attestation of GMP inspection for its Vapi facility, confirming EU GMP compliance for Dexamethasone under CEP No. 2024-138. No monetary value is disclosed.